HDAC9 and neoplasm: γδ T cells stimulated with HDMAPP and rIL2 in presence of HDAC inhibitors VPA (2 mM), TSA (100 nM), and SAHA (1 μM) for 72 h were used as effector against zoledronate-treated tumor cell lines (AW13516, COLO205 and Raji) as targets at E/T ratio of 40:1.